Research programme: COVID-19 compounds - Sunshine Biopharma/University of Georgia
Latest Information Update: 28 May 2025
At a glance
- Originator University of Georgia
- Developer Sunshine Biopharma; University of Georgia
- Class Antivirals
- Mechanism of Action Coronavirus papain like protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in Canada
- 28 May 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in USA
- 22 Apr 2021 Preclinical trials in COVID-2019 infections in Canada (unspecified route)